Related Experiment Video
Updated: Feb 5, 2026

Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
Published on: July 19, 2019
Changing strategies for target therapy in gastric cancer
Suk-Young Lee1, Sang Cheul Oh1
1Suk-young Lee, Sang Cheul Oh, Division of Oncology/Hematology, Department of Internal Medicine, College of Medicine, Korea University, Guro-gu, Seoul 08308, South Korea.
Abstract:
In spite of a worldwide decrease in the incidence of gastric cancer, this malignancy still remains one of the leading causes of cancer mortality. Great efforts have been made to improve treatment outcomes in patients with metastatic gastric cancer, and the introduction of trastuzumab has greatly improved the overall survival. The trastuzumab treatment took its first step in opening the era of molecular targeted therapy, however several issues still need to be resolved to increase the efficacy of targeted therapy. Firstly, many patients with metastatic gastric cancer who receive trastuzumab in combination with chemotherapeutic agents develop resistance to the targeted therapy. Secondly, many clinical trials testing novel molecular targeted agents with demonstrated efficacy in other malignancies have failed to show benefit in patients with metastatic gastric cancer, suggesting the importance of the selection of appropriate indications according to molecular characteristics in application of targeted agents. Herein, we review the molecular targeted agents currently approved and in use, and clinical trials in patients with metastatic gastric cancer, and demonstrate the limitations and future direction in treatment of advanced gastric cancer.
Insights
Molecular targeted therapy, including trastuzumab, has advanced gastric cancer treatment. However, resistance and trial failures highlight the need for better patient selection and new strategies for advanced gastric cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Gastric cancer remains a leading cause of cancer mortality globally, despite incidence decreases.
- Trastuzumab has improved survival in metastatic gastric cancer, initiating molecular targeted therapy.
- Challenges include resistance to trastuzumab and failures of novel agents in clinical trials.
Purpose of the Study:
- To review current molecular targeted agents and clinical trials for metastatic gastric cancer.
- To identify limitations in existing targeted therapies.
- To discuss future directions for advanced gastric cancer treatment.
Main Methods:
- Literature review of approved molecular targeted agents.
- Analysis of clinical trial data for advanced gastric cancer.
- Discussion of molecular characteristics influencing treatment efficacy.
Main Results:
- Trastuzumab has shown efficacy but faces resistance issues.
- Novel targeted agents have shown limited success in gastric cancer trials.
- Molecular profiling is crucial for selecting appropriate targeted therapies.
Conclusions:
- Targeted therapy for advanced gastric cancer shows promise but requires optimization.
- Overcoming resistance and improving patient selection are key challenges.
- Future research should focus on personalized treatment strategies based on molecular profiles.
More Related Videos
Related Concept Videos
Rates of Change
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Gastric Motility
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Gastric Emptying
Global Climate Change

